Identifying ALK+ NSCLC patients for targeted treatment

Roche announces FDA approval of companion diagnostic to identify ALK-positive lung cancer patients eligible for targeted therapy

 

> Read the media release

Guiding immunotherapy for non-small cell lung cancer

VENTANA PD-L1 (SP263) Assay label expanded to identify NSCLC patients eligible for treatment with KEYTRUDA® (pembrolizumab) in countries accepting the CE mark

[CE mark only, not FDA approved]

 

> Read the news release

Guiding immunotherapy for urothelial carcinoma

Roche expands VENTANA PD-L1 (SP263) Assay label ­– now FDA approved in the US to predict a urothelial carcinoma patient’s response to IMFINZI™ (durvalumab)

 

> Read the news release

Featured Stories



Tissue Expressions

Case Studies

USCAP 2017 Annual Meeting